Shares of Arcturus Therapeutics Ltd (NASDAQ:ARCT) have received an average recommendation of “Buy” from the nine brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $29.50.

A number of research analysts recently weighed in on the stock. Roth Capital raised their target price on shares of Arcturus Therapeutics from $14.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. HC Wainwright reaffirmed a “buy” rating and issued a $62.00 target price on shares of Arcturus Therapeutics in a research report on Monday, May 4th. Zacks Investment Research downgraded shares of Arcturus Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Robert W. Baird reiterated a “buy” rating and issued a $26.00 price target on shares of Arcturus Therapeutics in a research note on Wednesday, March 18th. Finally, Guggenheim assumed coverage on shares of Arcturus Therapeutics in a research note on Thursday, February 6th. They issued a “buy” rating and a $19.00 price target for the company.

Arcturus Therapeutics stock opened at $45.24 on Thursday. The company has a market cap of $755.37 million, a P/E ratio of -21.96 and a beta of 3.19. Arcturus Therapeutics has a 1-year low of $5.75 and a 1-year high of $51.20. The company has a fifty day simple moving average of $24.04 and a 200 day simple moving average of $14.75.

Arcturus Therapeutics (NASDAQ:ARCT) last released its earnings results on Thursday, May 7th. The biotechnology company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). The business had revenue of $2.65 million during the quarter, compared to the consensus estimate of $7.52 million. Arcturus Therapeutics had a negative net margin of 151.34% and a negative return on equity of 409.05%. As a group, analysts predict that Arcturus Therapeutics will post -2.71 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in ARCT. Cormorant Asset Management LP bought a new position in Arcturus Therapeutics in the 1st quarter valued at about $3,561,000. ARK Investment Management LLC grew its holdings in shares of Arcturus Therapeutics by 8.6% during the 4th quarter. ARK Investment Management LLC now owns 1,383,756 shares of the biotechnology company’s stock valued at $15,041,000 after purchasing an additional 109,343 shares during the last quarter. Credit Suisse AG bought a new stake in shares of Arcturus Therapeutics during the 4th quarter valued at approximately $641,000. Bank of Montreal Can bought a new stake in shares of Arcturus Therapeutics during the 4th quarter valued at approximately $608,000. Finally, Morgan Stanley grew its holdings in shares of Arcturus Therapeutics by 27.4% during the 1st quarter. Morgan Stanley now owns 202,239 shares of the biotechnology company’s stock valued at $2,749,000 after purchasing an additional 43,497 shares during the last quarter. 30.10% of the stock is currently owned by hedge funds and other institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally.

Further Reading: How are capital gains distributions different for tax-deferred account?

Analyst Recommendations for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.